L
Luca Santarelli
Researcher at Hoffmann-La Roche
Publications - 50
Citations - 10300
Luca Santarelli is an academic researcher from Hoffmann-La Roche. The author has contributed to research in topics: Receptor & Gantenerumab. The author has an hindex of 26, co-authored 48 publications receiving 9584 citations. Previous affiliations of Luca Santarelli include Columbia University.
Papers
More filters
Journal ArticleDOI
SMN2 splicing modifiers improve motor function and longevity in mice with spinal muscular atrophy
Nikolai Naryshkin,Marla Weetall,Amal Dakka,Jana Narasimhan,Xin Zhao,Zhihua Feng,Karen K. Y. Ling,Gary Mitchell Karp,Hongyan Qi,Woll Matthew G,Guangming Chen,Nanjing Zhang,Vijayalakshmi Gabbeta,Priya Vazirani,Anuradha Bhattacharyya,Bansri Furia,Nicole Risher,Josephine Sheedy,Ronald Kong,Jiyuan Ma,Anthony Turpoff,Chang-Sun Lee,Xiaoyan Zhang,Young-Choon Moon,Panayiota Trifillis,Ellen Welch,Joseph M. Colacino,John Babiak,Neil Gregory Almstead,Stuart W. Peltz,Loren A. Eng,Karen S. Chen,Jesse L. Mull,Maureen S. Lynes,Lee L. Rubin,Paulo Fontoura,Luca Santarelli,Daniel Haehnke,Kathleen D. McCarthy,Roland Schmucki,Martin Ebeling,Manaswini Sivaramakrishnan,Chien-Ping Ko,Sergey Paushkin,Hasane Ratni,Irene Gerlach,Anirvan Ghosh,Friedrich Metzger +47 more
TL;DR: Small molecules that alter splicing of a specific messenger RNA have beneficial effects in a model of a motor neuron disease and selective SMN2 splicing modifiers may have therapeutic potential for patients with SMA.
Journal ArticleDOI
Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab
Susanne Ostrowitzki,Dennis Deptula,Lennart Thurfjell,Frederik Barkhof,Bernd Bohrmann,David J. Brooks,William E. Klunk,Elizabeth Ashford,Kisook Yoo,Zhi-Xin Xu,Hansruedi Loetscher,Luca Santarelli +11 more
TL;DR: Gantenerumab treatment resulted in a dose-dependent reduction in brain amyloid level, possibly through an effector cell-mediated mechanism of action.
Journal ArticleDOI
A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease.
Susanne Ostrowitzki,Robert Lasser,Ernest Dorflinger,Philip Scheltens,Frederik Barkhof,Frederik Barkhof,Tania Nikolcheva,Elizabeth Ashford,Sylvie Retout,Carsten Hofmann,Paul Delmar,Gregory Klein,Mirjana Andjelkovic,Bruno Dubois,Mercè Boada,Kaj Blennow,Luca Santarelli,Paulo Fontoura +17 more
TL;DR: The study was stopped early for futility, but dose-dependent effects observed in exploratory analyses on select clinical and biomarker endpoints suggest that higher dosing with gantenerumab may be necessary to achieve clinical efficacy.
Journal ArticleDOI
Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors.
TL;DR: While the 5-HT1B knockout mice are more aggressive, more reactive, and less anxious than the wild-types, the 5 -HT1A knockouts are less reactive, more anxious, and possibly less aggressive than theWild-types.
Journal ArticleDOI
Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-related behaviors and increases serotonergic function.
Luca Santarelli,Gabriella Gobbi,Pierre C. Debs,Etienne Sibille,Pierre Blier,René Hen,Mark J.S. Heath +6 more
TL;DR: It is shown that both genetic disruption and acute pharmacological blockade of the NK1R in mice result in a marked reduction of anxiety and stress-related responses and suggest that this effect is at least in part mediated by changes in the 5-HT system.